First Time Loading...

Merck & Co Inc
NYSE:MRK

Watchlist Manager
Merck & Co Inc Logo
Merck & Co Inc
NYSE:MRK
Watchlist
Price: 128.26 USD -0.42% Market Closed
Updated: May 3, 2024
Section:
 

Relative Value

The Relative Value of one MRK stock under the Base Case scenario is 143.85 USD. Compared to the current market price of 128.26 USD, Merck & Co Inc is Undervalued by 11%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MRK Relative Value
Base Case
143.85 USD
Undervaluation 11%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.3
P/S
P/S
Price to Sales
5.3
vs History
6
vs Industry
25
Median 3Y
4.4
Median 5Y
4.3
Industry
2.4
Forward
5
More Details
140.8
P/E
P/E
Price to Earnings
140.8
vs History
7
vs Industry
1
Median 3Y
24.2
Median 5Y
20.2
Industry
22.9
Forward
14.8
More Details
25
P/OCF
P/OCF
Price to OCF
25
vs History
3
vs Industry
19
Median 3Y
15.2
Median 5Y
15.2
Industry
17.1
More Details
25.6
P/FCFE
P/FCFE
Price to FCFE
25.6
vs History
17
vs Industry
20
Median 3Y
19
Median 5Y
17.7
Industry
23.2
More Details
8.6
P/B
P/B
Price to Book Value
8.6
vs History
3
vs Industry
7
Median 3Y
5.9
Median 5Y
6.3
Industry
2.1
More Details
5.7
EV/S
EV/S
Enterprise Value to Sales
5.7
vs History
9
vs Industry
23
Median 3Y
4.8
Median 5Y
4.6
Industry
2.6
Forward
5.4
More Details
7.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.6
vs History
11
vs Industry
29
Median 3Y
6.6
Median 5Y
6.6
Industry
5.1
More Details
33.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
33.5
vs History
7
vs Industry
10
Median 3Y
14.1
Median 5Y
13.6
Industry
13.6
Forward
12.2
More Details
53.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
53.1
vs History
7
vs Industry
7
Median 3Y
17
Median 5Y
17.8
Industry
17
Forward
13.5
More Details
27
EV/OCF
EV/OCF
Enterprise Value to OCF
27
vs History
3
vs Industry
17
Median 3Y
16.6
Median 5Y
16.7
Industry
15.8
More Details
38.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
38.4
vs History
3
vs Industry
13
Median 3Y
24.8
Median 5Y
22.8
Industry
17.6
More Details
3.7
EV/IC
EV/IC
Enterprise Value to IC
3.7
vs History
3
vs Industry
23
Median 3Y
2.9
Median 5Y
2.7
Industry
1.9
More Details

Multiples Across Competitors

MRK Competitors Multiples
Merck & Co Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Merck & Co Inc
NYSE:MRK
324.7B USD 5.3 140.8 33.5 53.1
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
717.6B USD 21 136.9 61.8 71
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 16.8 46.5 34 37.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
360.9B USD 4.4 8.9 11.9 15.7
UK
AstraZeneca PLC
LSE:AZN
188.4B GBP 5.2 39.7 140.8 225.8
CH
Novartis AG
SIX:NOVN
181.7B CHF 4.3 13.4 9.8 16.3
CH
Roche Holding AG
SIX:ROG
170.7B CHF 2.9 14.8 8.5 10.1
US
Pfizer Inc
NYSE:PFE
156.4B USD 2.7 73.8 11 16.3
FR
Sanofi SA
PAR:SAN
115.2B EUR 2.5 21.3 8.1 11.8
P/E Multiple
Earnings Growth
US
Merck & Co Inc
NYSE:MRK
Average P/E: 55.1
140.8
7 454%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
136.9
346%
DK
Novo Nordisk A/S
CSE:NOVO B
46.5
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
8.9
-20%
UK
AstraZeneca PLC
LSE:AZN
39.7
168%
CH
Novartis AG
SIX:NOVN
13.4
15%
CH
Roche Holding AG
SIX:ROG
14.8
26%
US
Pfizer Inc
NYSE:PFE
73.8
680%
FR
Sanofi SA
PAR:SAN
21.3
120%

See Also

Summary
MRK intrinsic value, competitors valuation, and company profile.
DCF Valuation
MRK stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MRK stock valuation using valuation multiples.
Wall Street Estimates
MRK price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MRK stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 133,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.